[Management of conjunctival malignant @entity320 associated with primary acquired XXXX (PAM) using 0.02% @entity1138 eyedrops].

@entity1 @entity1803 @entity5 @entity1138 @entity1709 @entity320
BACKGROUND: The therapy of malignant diseases of the conjunctiva with local chemotherapy is an extension of the therapeutic options in this field. We report on our experience in the therapy of @entity320 of the conjunctiva associated with primary acquired @entity1709 (PAM). METHODS AND @entity1 : Between March 1998 and April 2001, 13 @entity1 with @entity320 associated with PAM (6 female; 7 male; mean age 57+/-13 years) were treated with local chemotherapy. The @entity5 was classified as stage pT2 (pN0, pM0) in seven @entity1 , stage @entity1803 (pN0, pM0) in three @entity1 and in the remaining three @entity1 the lid was involved in the malignant process (pT4, pN0, pM0). Local chemotherapy ( @entity1138 0.02% eyedrops 5 times a day) was applied after incisional biopsies in 2 cycles for 14 days with a 14-day break. In 4 @entity1 a third cycle was included. RESULTS: Regression of the @entity5 was observed after completion of the therapy in all cases. Severe ocular or systemic secondary effects were not seen in our @entity1 . Nine @entity1 were without recurrence within the follow-up time. In three @entity1 , a recurrence of the disease was observed. In these cases, the eyelid was involved in the process. CONCLUSION: Local chemotherapy with @entity1138 is a useful option in the treatment of @entity320 of the conjunctiva associated with PAM if the @entity5 stage is @entity1803 or less. From our point of view the combination with incisional biopsy is of great benefit. Prognosis of @entity320 involving the lid margin (pT4) is poor.
